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ABSTRACT
Purpose: Imaging features of sinusoidal obstruction syndrome (SOS), 
an increasingly common drawback of chemotherapy, were evaluated via 
18F-fluorodeoxyglucose (FDG) positron emission tomography computed tomography 
(PET/CT).
Experimental Design: This retrospective study was approved by our Institutional 
Review Board, with a waiver of informed consent. FDG PET/CT studies of 35 patients 
(male, 24; female, 11; median age, 53.2 years) obtained between January, 2005 and 
December, 2012 were analyzed before and after systemic chemotherapy. Diagnosis of 
SOS was based on histologic (n=13) or gadoxetic acid-enhanced MRI (n=22) findings. 
On PET/CT images, ROIs drawn on non-tumorous liver generated mean standardized 
uptake value (SUVliver). Total lesion glycolysis of liver (TLGliver) was calculated as: 
SUVliver × CT-derived hepatic volume. Paired t-test was applied to compare changes 
before and after SOS.
Results: Mean (±standard error [SE]) values of hepatic volume (baseline, 
1307.7±46.2 cm3; SOS, 1395.4±41.3 cm3; p=0.004), SUVliver (baseline, 2.08±0.06; 
SOS, 2.27±0.07; p=0.02), and TLGliver (baseline, 2697.5±114.5; SOS, 3170.2±134.2; 
p=0.001) significantly increased with development of SOS. In contrast, mean SUVaorta 
was unchanged (baseline, 1.53±0.04; SOS, 1.50±0.04; p=0.52). 
Conclusions: Hepatic FDG uptake on PET/CT intensified after onset of SOS 
and thus may be an inappropriate reference in this setting, potentially skewing 
chemotherapeutic responses gauged by lesion-to-liver SUV ratio.
INTRODUCTION
Recent advances in chemotherapeutic regimens, 
surgical techniques, and imaging studies have markedly 
improved treatment outcomes in various types of cancer 
[1-4]. Regimens incorporating oxaliplatin and cisplatin 
have significantly improved treatment response rates, 
enabling surgical resection of initially unresectable liver 
metastases in carefully selected patients [5-9]. However, 
these newer agents are not without side effects and often 
induce hepatic sinusoidal obstruction syndrome (SOS) 
[10]. As their usage increases, a commensurate upsurge in 
SOS may well be anticipated. 
Although SOS is not life-threatening to the 
majority of sufferers, its detection has important clinical 
ramifications in certain patients. Hematopoietic stem cell 
transplant recipients are particularly vulnerable to SOS, 
with reported mortality of ~80-90% [11, 12]. Furthermore, 
patients with hepatic SOS are more prone to bleeding and 
therefore are at greater risk of intra- and post-operative 
complications [13-15].
Radiologic findings indicative of SOS are well 
known, reflecting the morphology that is manifested 
in liver [16]. Heterogeneous hepatic parenchymal 
enhancement during the portal phase of CT has been 
described in SOS and may be diffuse, peripheral, 
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or multifocal in distribution [17]. Reticular hepatic 
hypointensity on the hepatobiliary phase of gadoxetic 
acid-enhanced MRI is also a highly specific feature of 
SOS [18-20]. As such, we assumed that these SOS-related 
morphologic and/or functional changes would similarly 
appear on 18F-fluorodeoxyglucose positron emission 
tomography/computed tomography (FDG PET/CT) 
imaging.
FDG PET/CT enables non-invasive whole-body 
imaging of glucose metabolism and has been increasingly 
utilized to predict responses to systemic chemotherapy in 
patients with cancer. Nevertheless, only one case report 
of SOS-related PET/CT imaging attributes is currently 
found in the literature [21]. Moreover, the liver-to-lesion 
SUV ratio (SUVlesion/SUVliver) determinable by PET/CT is 
a frequent means of assessing tumor treatment response. 
Thus any change in SUVliver during development of SOS 
is of considerable importance.
The purpose of this study was to investigate hepatic 
FDG PET/CT findings in the context of SOS, comparing 
PET/CT scans performed before and after its development.
RESULTS
SOS-related changes in metabolism, serum 
analytes, and platelet count
The basic demographic and clinical characteristics 
of patients with SOS are provided in Figure 1 and Table 1. 
Changes in metabolic and biochemical indices of patients 
with SOS and control group are summarized in Table 2 
and supplementary Table 1, respectively.
 Following onset of SOS, mean patient weight 
significantly declined (baseline, 61.7±1.5 Kg; SOS, 
59.6±1.7 Kg; p = 0.014), whereas mean serum levels of 
bilirubin (baseline, 0.47±0.03 mg/dL; SOS, 0.76±0.06 mg/
dL; p < 0.001), aspartate transaminase (baseline, 24.3±3.7 
IU/L; SOS; 50.9±11.7 IU/L; p = 0.032), and alkaline 
phosphatase (baseline, 66.5±3.7 IU/L; SOS, 90.6±6.1 
IU/L; p < 0.001) increased significantly. Other indices, 
namely alanine transaminase (p = 0.09), and creatinine 
(p = 0.22), similarly tended to increase, but not to a 
statistically significant extent. A significant reduction in 
mean platelet count (baseline, 258.4±14.9 103/uL; SOS, 
161.1±16.7 103/uL; p < 0.001) was also observed. 
SOS-related changes in organ volume and FDG 
PET/CT parameters
Changes in hepatic and splenic volumes and in 
PET/CT indices of patients with SOS are listed in Table 
3. Mean sizes of liver (baseline, 1307.7±46.2 cm3; SOS, 
1395.4±41.3 cm3; mean change, 87.7±28.7 cm3; % change, 
8.5%; p = 0.004) and spleen (baseline, 164.6±10.9 cm3; 
SOS; 240.5±15.8 cm3; mean change, 76.5±12. cm3; 
% change, 51.3%, p = 0.001) increased significantly 
following onset of SOS (Table 3). In contrast, no 
significant change in the hepatic and splenic volume was 
observed in the control group (Supplementary Table 2).
All metabolic indices indicated a significant upsurge 
in hepatic FDG uptake (relative to baseline FDG PET/
CT) following onset of SOS, with a significant rise in 
mean SUVliver (baseline, 2.08±0.06; SOS, 2.27±0.07; 
% change, 12.2%; p = 0.02) and in the blood pool-
adjusted SUVratio (baseline, 1.36±0.02; SOS, 1.53±0.03; 
Table 1: Demographic and clinical characteristics of patient population
Characteristics Data(n=35)
Age, median (range) 53.2 (34.7–78.9)
Gender (M:F) 24 (69%) : 11 (31%)
Primary malignancy (n,%) 35 (100%)
    Colon/rectum 17 (49%)
    AGC/duodenum 12 (34%)
    Pancreas/AOV 3 (9%)
    GIST 1 (3%)
    Lymphoma 1 (3%)
    Ovary 1 (3%)
Chemotherapy (n) 35 (100%)
    Oxaliplatin-based 
           (Eloxatin/Oxalitin/Pleoxtin)
28 (80%)
(19/7/2)
    Cisplatin-based 6 (17%)
    CHOP 1 (3%)
Interval between chemotherapy and second PET/CT (months) 5.6 ± 3.0
AGC: advanced gastric cancer; GIST: gastrointestinal stromal tumor; AOV: ampulla of Vater
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Figure 1: Eligibility criteria of study population
Figure 2: Intensified FDG uptake in patient developing SOS. A.-C. Baseline 18F-FDG PET/CT: A. Maximum intensity 
projection (MIP) image of 74 year-old woman with ascending colon cancer and multiple hepatic metastases (arrows); B. axial PET images 
(mean SUV, 2.3; hepatic volume, 1134.5 mm3; TLG, 2609.35); and C. hepatobiliary phase image of gadoxetic acid-enhanced MRI (prior 
to oxaliplatin chemotherapy). D.-F. 18F-FDG PET/CT after FOLFOX regimen (8 cycles): D. Maximum intensity projection (MIP) image 
showing diffuse increase in hepatic FDG uptake. Multiple hepatic metastases are observed (arrows); E. axial PET image (mean SUV, 
2.6; hepatic volume, 1205.3 mm3; TLG, 3133.78); and F. hepatobiliary phase of gadoxetic acid-enhanced MRI. G. Microscopic view of 
surgically resected tumor-free liver with morphologic changes of sinusoidal obstructive syndrome such as diffuse sinusoidal dilatation and 
intracytoplasmic cholestasis (arrows), (H&E stain ×100).
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% change, 12.8%; p < 0.001) (Figure 2). Mean TLGliver 
also increased significantly (baseline, 2697.5±114.5; 
SOS, 3170.1±134.2; increment, 472.7±124.5; % 
change, 21.0%; p = 0.001), signaling a rise in metabolic 
glycolysis. Mean SUVaorta remained unchanged (baseline, 
1.53±0.04; SOS, 1.50±0.04; % change, -0.04%; p = 0.52) 
(Table 3). Meanwhile, no significant alteration in the 
SUVliver, SUVaorta, SUVratio and TLGliver between the first 
and second PET/CT was observed in the control group 
(Supplementary Table 2).
Severity of SOS and FDG PET/CT
As set forth by Chao [22], SOS in our cohort was 
graded as mild (n = 23), moderate (n = 9), or severe (n = 
3), using the highest rank warranted by at least one of four 
determinants; and patients were stratified as mild (n = 23) 
or moderate/severe (n = 12) for correlation with imaging 
indices. Compared with the mild SOS subset, TLGliver 
trended higher in patients with moderate/severe SOS 
(2995.7±144.0 vs 3504.7±259.7; p = 0.104), falling short 
of statistical significance, whereas mean splenic volume 
(212.6±18.1 vs 291.6±24.7 ; p = 0.017) and mean TLGspleen 
(363.6±28.5 vs 536.4±51.8; p = 0.003) were significantly 
higher. Other metabolic or imaging indices did not differ 
significantly by severity of SOS (Table 4). 
DISCUSSION
In this study, we have demonstrated that hepatic 
FDG uptake on PET/CT increases after onset of SOS. 
To the best of our knowledge, only one published case 
report has similarly delineated this relationship. Known 
risk factors of SOS, such as adjuvant or neo-adjuvant 
chemotherapy, hematopoietic stem cell transplantation, 
and liver transplantation [13, 22, 23], should be sought 
when interpreting PET/CT images. Prior oxaliplatin-
based chemotherapy is a critical factor, given that the 
risk of subsequent SOS is considerable (18.9-79%) [24-
26]. CT and/or MRI imaging conducted in parallel may 
provide further diagnostic support. Hallmark features of 
SOS include heterogeneous parenchymal enhancement 
on contrast-enhanced dynamic liver studies and/or 
reticular hypointensity during hepatobiliary phase of a 
gadoxetic acid-enhanced MRI [17-20]. Hepatic or splenic 
enlargement, readily detectable in imaging studies, is 
also characteristic of SOS (Table 3). A suspected shift 
in hepatic FDG uptake may be exposed through careful 
comparison of sequential PET/CT studies (current vs 
baseline) in terms of SUVliver.
Because PET/CT is frequently utilized to gauge 
chemotherapeutic response, hepatic FDG uptake is 
an important clinical parameter, serving in general as 
Table 2: Comparison of biochemical indices in patients developing SOS
Baseline SOS Mean change 95% confidence p-value
Weight (kg) 61.7±1.5 59.6±1.7 -2.0±0.8 -3.6–-0.4 0.014*
Bilirubin (mg/dL) 0.47±0.03 0.76±0.06 0.29±0.05 0.2–0.4 <0.001*
AST (IU/L) 24.3±3.7 50.9±11.7 26.6±11.9 2.3–50.8 0.032*
ALT (IU/L) 21.9±3.6 44.3±12.4 22.3±12.6 3.2–47.8 0.09
Cr (mg/dL) 0.83±0.03 0.79±0.03 0.03±0.03 -0.09–0.02 0.22
CEA (ng/mL) 11.6±3.4 5.0±1.1 -6.6±3.1 -13.0–-0.2 0.044*
ALK (IU/L) 66.5±3.7 90.6±6.1 24.1±5.2 15.5–34.8 <0.001*
Platelet count (×103/uL) 258.4±14.9 161.1±16.7 -97.3±23.5 -145.1–-49.5 <0.001*
Glucose 93.0±9.1 94.3±13.1 1.3±13.8 -3.7–6.3 0.595
* Statistically significant (paired t-test)
Indices expressed as mean±SE
Table 3: Comparison of PET/CT parameters in patients developing SOS
Baseline SOS Mean change 95% confidence p-value % change
Hepatic volume (cm3) 1307.7±46.2 1395.4±41.3 87.7±28.7 29.4–146.0 0.004* 8.5±2.6
Splenic volume (cm3) 164.6±10.9 240.5±15.8 76.5±12.0 52.0–101.0 0.001* 51.3±7.5
SUVliver 2.08±0.06 2.27±0.07 0.19±0.08 0.04–0.35 0.02* 12.2±4.4
SUVaorta 1.53±0.04 1.50±0.04 -0.03±0.05 -0.13–0.07 0.52 -0.04±3.5
SUVratio 1.36±0.02 1.53±0.03 0.16±0.04 0.09–0.24 <0.001* 12.8±2.7
TLGliver 2697.5±114.5 3170.2±134.22 472.7±124.5 219.7–725.6 0.001* 21.0±4.7
SUVspleen 1.66±0.07 1.79±0.06 0.13±0.07 0.01–0.28 0.074 12.0±4.5
TLGspleen 268.9±18.5 424.6±29.3 155.7±25.9 102.9–208.5 0.001* 68.7±10.5
Parameters expressed as mean±SE, * Statistically significant (paired t-test)
TLGliver: total lesion glycolysis of liver; SUVratio (Liver-to-blood ratio) =  SUVliver / SUVaorta
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a standard reference. Hence, FDG uptake by various 
tumors may be compared within or among individuals by 
calculating lesion-to-liver SUV ratio (SUVlesion/SUVliver). 
This strategy, based on an authenticated concept that 
SUVliver is quite stable over time [27], is also integral to 
the PET Response Criteria in Solid Tumors (PERCIST) 
1.0 protocol. The latter guides therapeutic response 
determinations, utilizing liver to normalize SUL (i.e., lean 
body mass SUV) . 
Our findings instead indicate that hepatic FDG 
uptake can be affected by the development of SOS, and 
as a result sometimes may change rather than remain 
constant. In our cohort, approximately 10% increase in 
SUVliver was observed on PET/CT (relative to baseline) 
after onset of SOS (Table 3). Consequently, the lesion-to-
liver SUV ratio (SUVlesion/SUVliver) will decline by default, 
and may have more or less influence on the interpretation 
of chemotherapy response assessment. Furthermore, 
SOS is a dynamic process, subject to aggravation, 
improvement, or resolution [22, 26]. Therefore, SUVliver 
may actually vacillate (as would lesion-to-liver SUV 
ratio and even SUL) in this setting, rather than simply 
increasing, according to phase of disease. However, we 
found no statistically significant difference in SUVliver 
determinations when stratifying patients by severity of 
SOS (Table 4).
On the other hand, SUVaorta remained consistent, 
regardless of whether or not SOS developed (Table 3, 4). 
According to PERSIST (1.0), if the liver is diseased and 
not suitable to serve as a reference, the blood pool activity 
in descending aorta is an acceptable alternative [28]. In 
view of this finding, we advise all pertinent specialists to 
be cognizant of SOS and its clinical presentation and urge 
that descending aorta (rather than liver) serve as diagnostic 
reference.
The mechanism for intensification of hepatic FDG 
uptake with onset of SOS is unclear. Focal or diffuse 
FDG uptake by tissues (organ or lesion) is typically 
attributed to heightened blood flow or glucose metabolism. 
Decreased washout and stasis of radiotracer are alternative 
explanations. Toxic injuries to endothelium have been 
implicated in SOS, which is histologically characterized 
by sinusoidal dilatation with peliosis, nodular regenerative 
hyperplasia, and fibrosis [29]. We speculate that 
microcirculatory disturbances due to endothelial cell 
injury and stasis of blood in peliosis may produce hepatic 
congestion, thereby passively increasing the blood-pool 
FDG tracer activity. In the sole case report to date, which 
formally documented a correlation between FDG uptake 
and SOS [21], trapping of FDG within dilated sinusoids 
was offered as explanation. Inflammation seemed less 
likely, considering its conspicuous absence from liver 
biopsy [21]. 
This investigation has several acknowledged 
limitations. Although histologic confirmation of SOS was 
not routinely achieved, we contend that gadoxetic acid-
enhanced MRI is a modality with high specificity for SOS 
and is a reliable mode of diagnosis, based on published 
evidence. Our imaging protocol was also fraught with 
inconsistency (e.g., intervals between baseline and follow-
up PET/CT), as an inherent retrospective constraint. 
In addition, we have assumed that accumulated FDG 
in congested sinusoids is the basis for intensified FDG 
uptake in patients with SOS. To evaluate this hypothesis, 
a dynamic FDG PET/CT protocol is needed, well beyond 
the scope of this study. Future efforts should explore this 
method in assessing or grading the severity of SOS. As a 
final note, we were unable to validate our hypothesis that 
a rise in SUVliver with onset of SOS may artifactually skew 
the lesion-to-liver SUV ratio, causing misinterpretation of 
treatment response. Subsequent research should address 
this issue.
In conclusion, we have found that SOS is associated 
with a rise in mean SUVliver on PET/CT, relative to 
baseline status. Clinical awareness of this phenomenon is 
paramount, given that chemotherapy predisposes to SOS. 
The reduced lesion-to-liver SUV ratio (SUVlesion/SUVliver) 
that results may create a false impression of therapeutic 
efficacy. 
Table 4: Comparison of PET/CT indices by severity of SOS
Mild SOS
 (n = 23)
Moderate/severe SOS
 (n = 12) p-value
Hepatic volume (cm3) 1368.6±55.4 1446.9±56.8 0.376
SUVliver 2.2±0.1 2.4±0.2 0.178
SUVaorta 1.5±0.04 1.5±0.1 0.52
SUVratio 1.5±0.03 1.6±0.1 0.234
TLGliver 2995.7±144.0 3504.7±259.7 0.104
Age 55.6±2.53 55.5±3.27 0.975
Splenic volume (cm3) 212.6±18.1 291.6±24.7 0.017*
SUVspleen 1.8±0.1 1.8±0.1 0.534
TLGspleen 363.6±28.5 536.4±51.8 0.003*
* Statistically significant




The study protocol was approved by our Institutional 
Review Board, with a waiver of informed consent. This 
was a retrospective study for which all data were kept 
anonymous. Utilizing the facility’s electronic clinical 
database, patients undergoing FDG PET/CT between 
January, 2005 and December, 2012 qualified as potential 
candidates. Inclusion criteria were as follows: 1) recipients 
of systemic cancer chemotherapy, 2) diagnosis of hepatic 
SOS, based on either histopathology of surgical specimens 
(n = 13) or gadoxetic acid-enhanced MRI (n = 22) findings, 
and 3) two FDG PET/CT studies at minimum, done at 
baseline (prior to chemotherapy) and within 15 days of 
diagnosing SOS (Figure 1). Any diagnosis of SOS arrived 
at solely by gadoxetic acid-enhanced MRI was reviewed 
by two radiologists (H.K. and S-E.B.), accruing 4 and 
7 years of experience in liver imaging, respectively. A 
consensus was reached on whether imaging characteristics 
of SOS were present, namely normal appearing hepatic 
parenchyma on baseline dynamic contrast-enhanced 
CT and MRI (if available) and unequivocal diffuse and 
heterogeneous hepatic parenchymal signal hypointensity 
on hepatobiliary phase image of gadoxetic acid-enhanced 
MRI in the aftermath of systemic chemotherapy [18-20]. 
Ultimately, 35 patients were recruited for study, 
each diagnosed with SOS and having the requisite FDG 
PET/CT studies at baseline and after diagnosis of SOS. 
The following clinical parameters (obtained within 3 
days of FDG PET/CT) were recorded to gauge severity 
of SOS: weight, bilirubin, aspartate transaminase, alanine 
transaminase, creatinine, carcinoembryonic antigen, 
alkaline phosphatase, and platelet count. Patients were 
then categorized as mild, moderate, or severe SOS, as 
suggested by Chao [22]. 
Patient demographics
A total of 35 patients (median age, 53.2 years; range, 
34.7-78.9 years) met our study criteria, including 24 men 
(median age, 55.1 years; range, 42.6-78.9 years) and 11 
women (median age, 50.5 years; range, 34.7-74.9 years) 
whose treated cancers varied in origin (gastrointestinal 
tract, 29; pancreas, 3; gastrointestinal stromal tumor 
[GIST], 1; lymphoma, 1; ovary, 1) (Table 1). In the vast 
majority of patients (28/35, 80.0%), SOS developed 
after oxaliplatin-based chemotherapy. Six patients 
received cisplatin, and only one was given a regimen 
of CHOP (cyclophosphamide, doxorubicin, vincristine, 
and prednisone) (Table 1). Duration of treatment ranged 
from 65-330 days (mean, 152.3±70.5 days). The interval 
between baseline and second PET/CT ranged from 3.0-
57.1 months (mean, 11.5±11.8 months). The interval 
between starting chemotherapy and second PET/CT was 
on average 5.6 months ± 3.0 months.
In parallel, we defined a control group of 35 
individuals (24 males, 11 females; median age, 52.9 years; 
range, 34.4-78.9 years). These patients did not have any 
history of malignancy and underwent PET/CT at least 
twice for health examination. The interval between first 
and second PET/CT was 22.3 months ± 13.3 months.
Gadoxetic acid-enhanced MRI protocol
In 22 patients, diagnosis of SOS relied on gadoxetic 
acid-enhanced MRI views generated by 3-T (Magnetom 
Tim Trio; Siemens Medical Solutions, Erlangen, 
Germany) or 1.5-T (Interna Achieva; Philips Healthcare, 
Best, The Netherlands) imaging unit. Routine in-phase 
and opposed-phase T1- and T2-weighted images were 
obtained. The contrast-enhanced dynamic study protocol 
at our facility consisted of a breath-hold transverse 3D 
GRE (TR/TE, 2.5/0.9 msec; flip angle, 13°; FOV, 38 cm; 
matrix, 320 × 224; section thickness, 2 mm; no gap for 
3T unit or TR/vTE, 4.4/2.1 msec; flip angle, 15°; FOV, 38 
cm; matrix, 256 × 256; section thickness, 2 mm; no gap 
for 1.5T unit). 
To determine the scan delay for arterial phase 
imaging, a 1-mL test bolus injection technique was used. 
Contrast-enhanced MRI was performed using a breath-
hold 3D-GRE sequence following intravenous (IV) bolus 
administration of gadoxetic acid (0.025 mmol/kg body 
at 2 mL/s) and a 20-mL saline flush. Portal venous and 
transitional phase images were obtained ~30-40 seconds 
after acquisition of preceding images, done 20-35 s 
(arterial phase), 60-70 s (portal venous phase), 100-120 s 
and 150-180 s (transitional phase) from time of IV contrast 
injection. All images were oriented in transverse plane. 
Hepatobiliary phase images were acquired 15-20 min 
after gadoxetic acid injection in identical manner. Imaging 
parameters were individualized as needed.
PET/CT protocol and imaging analysis
All patients underwent routine FDG PET/CT scans 
(Discovery 600 PET/CT; GE Healthcare, Milwaukee, 
WI, USA), with fasting for at least 6 hours and confirmed 
peripheral blood glucose levels ≤140 mg/dl before FDG 
injection. FDG (~5.5 MBq/kg) was administered IV 1 
hour before image acquisition. After initial low-dose CT 
(Discovery 600: 30mA, 130 kVp), standard PET imaging 
was performed from neck to proximal thighs (acquisition 
time, 3 min/bed) in 3D mode. Image reconstruction was 
by ordered subset expectation maximization (2 iterations, 
20 subsets).
Studies were displayed on a GE AW 4.0 workstation 
(GE Healthcare, Milwaukee, WI, USA) for review 
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by a nuclear medicine specialist (A.C.) with 10 years 
of experience. Region of interest (ROI) was drawn in 
triplicate on non-tumorous hepatic parenchyma. SUVs 
were normalized to body weight. Mean SUV (SUVliver) 
was recorded and total lesion glycolysis of the liver 
(TLGliver) was calculated as SUVliver × CT-derived hepatic 
volume (cm3). Mean SUV of aorta (SUVaorta) was similarly 
obtained, drawing three 1-cm ROIs on abdominal aorta 
and recording the average. Liver-to-blood ratio (SUVratio) 
was calculated as the ratio between SUVliver divided by 
SUVaorta (SUVliver / SUVaorta). These five indices (hepatic 
volume, SUVliver, TLGliver, SUVaorta, and SUVratio,) were 
compared at baseline and in conjunction with SOS to 
evaluate relative change in liver glycolysis.
Hepatic and splenic volumes were determined by a 
radiologist (H.K.) with 4 years of experience in hepatic 
imaging. To do so, CT axial images were archived in 
Digital Imaging and Communications in Medicine 
(DICOM) format and stored on a GE AW 4.0 workstation 
(GE Healthcare). An ROI was drawn along the margins 
of liver or spleen on each slice, and total organ volumes 
were reached additively, combining ROIs of consecutive 
images. The following formula was applied to determine 
% change rate (%) of each parameter: (ParameterFirst PET/
CT - ParameterSecond PET/CT)/ParameterFirst PET/CT.
Statistical analysis
Statistical analyses relied on standard software 
(SPSS v19; SPSS Inc., Chicago, IL, USA). All clinical and 
imaging data were assessed for normality as continuous 
variables, using the Kolmogorov-Smirnov test at p > 0.05 
to fulfill the normality assumption. Parametric analyses 
were applied to normally distributed variables. Paired 
t-test was utilized to compare changes in clinical and 
imaging indices before and after development of SOS. 
Patients were stratified as mild SOS or moderate/severe 
SOS to improve analytic clarity, and Student’s t-test was 
engaged for evaluating differences in imaging indices by 
degree of SOS. Statistical significance was set at p < 0.05. 
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